

# Etienne Simon-Lorire

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1638976/etienne-simon-loriere-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76  
papers

4,208  
citations

31  
h-index

64  
g-index

88  
ext. papers

6,991  
ext. citations

18.1  
avg, IF

5.5  
L-index

#	Paper	IF	Citations
76	SARS-CoV-2 Omicron emergence urges for reinforced One-Health surveillance.. <i>EMBO Molecular Medicine</i> , <b>2022</b> , e15558	12	2
75	Towards SARS-CoV-2 serotypes?. <i>Nature Reviews Microbiology</i> , <b>2022</b> ,	22.2	8
74	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103934	8.8	2
73	Antibody escape and global spread of SARS-CoV-2 lineage A.27.. <i>Nature Communications</i> , <b>2022</b> , 13, 115217.4	17.4	5
72	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	22
71	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.. <i>Immunity</i> , <b>2022</b> ,	32.3	2
70	Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.. <i>Nature Communications</i> , <b>2022</b> , 13, 2442	17.4	1
69	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.. <i>Nature</i> , <b>2021</b> ,	50.4	230
68	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , <b>2021</b> , 374, 423-431	33.3	35
67	A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. <i>Nature Communications</i> , <b>2021</b> , 12, 6277	17.4	2
66	A novel SARS-CoV-2 related coronavirus in bats from Cambodia. <i>Nature Communications</i> , <b>2021</b> , 12, 6563	17.4	37
65	Genomic surveillance of enterovirus associated with aseptic meningitis cases in southern Spain, 2015-2018. <i>Scientific Reports</i> , <b>2021</b> , 11, 21523	4.9	1
64	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , <b>2021</b> , 27, 917-924	50.5	355
63	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. <i>Nature</i> , <b>2021</b> , 596, 276-280	50.4	773
62	Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 1423-1432	5.5	8
61	Viral evolution sustains a dengue outbreak of enhanced severity. <i>Emerging Microbes and Infections</i> , <b>2021</b> , 10, 536-544	18.9	0
60	Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains. <i>Nature Communications</i> , <b>2021</b> , 12, 916	17.4	20

59	Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 57, 106274	14.3	24
58	Novel genome sequences of cell-fusing agent virus allow comparison of virus phylogeny with the genetic structure of populations. <i>Virus Evolution</i> , <b>2020</b> , 6, veaa018	3.7	12
57	Identification and molecular characterization of the first complete genome sequence of Human Parechovirus type 15. <i>Scientific Reports</i> , <b>2020</b> , 10, 6759	4.9	4
56	A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus. <i>Molecular Therapy</i> , <b>2020</b> , 28, 1772-1782	11.7	8
55	Genomic Epidemiology of 2015-2016 Zika Virus Outbreak in Cape Verde. <i>Emerging Infectious Diseases</i> , <b>2020</b> , 26, 1084-1090	10.2	11
54	Genetic Diversity of Collaborative Cross Mice Controls Viral Replication, Clinical Severity, and Brain Pathology Induced by Zika Virus Infection, Independently of. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	11
53	Molecular Characterization of Dengue Type 2 Outbreak in Pacific Islands Countries and Territories, 2017-2020. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5
52	FHL1 is a major host factor for chikungunya virus infection. <i>Nature</i> , <b>2019</b> , 574, 259-263	50.4	31
51	Does intravenous immunoglobulin therapy in Guillain-Barré syndrome patients interfere with serological Zika detection?. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 632-633	13.6	1
50	A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1424	8.4	39
49	Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 160-168	44.5	57
48	A Blood RNA Signature Detecting Severe Disease in Young Dengue Patients at Hospital Arrival. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1690-1698	7	14
47	Genetic Characterization of Enterovirus A71 Circulating in Africa. <i>Emerging Infectious Diseases</i> , <b>2018</b> , 24, 754-757	10.2	13
46	Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	8
45	Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006202	4.8	11
44	Optic neuropathy and congenital glaucoma associated with probable Zika virus infection in Venezuelan patients. <i>JMM Case Reports</i> , <b>2018</b> , 5, e005145	0.5	6
43	Non-congenital severe ocular complications of Zika virus infection. <i>JMM Case Reports</i> , <b>2018</b> , 5, e005152	0.5	7
42	Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans. <i>Viruses</i> , <b>2018</b> , 10,	6.2	20

41	Development and validation of four one-step real-time RT-LAMP assays for specific detection of each dengue virus serotype. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006381	4.8	35
40	Virus genomes reveal factors that spread and sustained the Ebola epidemic. <i>Nature</i> , <b>2017</b> , 544, 309-315	50.4	238
39	Autochthonous Japanese Encephalitis with Yellow Fever Coinfection in Africa. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1483-1485	59.2	58
38	Zika virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells. <i>EMBO Journal</i> , <b>2017</b> , 36, 1653-1668	13	77
37	Increased adaptive immune responses and proper feedback regulation protect against clinical dengue. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	45
36	Drivers of Dengue Intrahost Evolution. <i>Cell Host and Microbe</i> , <b>2017</b> , 22, 260-261	23.4	
35	Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. <i>Journal of Virology</i> , <b>2016</b> , 90, 9683-9692	6.6	47
34	Interferon-Induced Spermidine-Spermine Acetyltransferase and Polyamine Depletion Restrict Zika and Chikungunya Viruses. <i>Cell Host and Microbe</i> , <b>2016</b> , 20, 167-77	23.4	68
33	ZIKA virus elicits P53 activation and genotoxic stress in human neural progenitors similar to mutations involved in severe forms of genetic microcephaly. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2440	9.8	57
32	Human Adaptation of Ebola Virus during the West African Outbreak. <i>Cell</i> , <b>2016</b> , 167, 1079-1087.e5	56.2	134
31	Structural basis of potent Zika-dengue virus antibody cross-neutralization. <i>Nature</i> , <b>2016</b> , 536, 48-53	50.4	362
30	Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. <i>Nature</i> , <b>2015</b> , 524, 102-104	50.4	78
29	High Anti-Dengue Virus Activity of the OAS Gene Family Is Associated With Increased Severity of Dengue. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 2011-20	7	34
28	Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 280	8.4	109
27	Gene duplication is infrequent in the recent evolutionary history of RNA viruses. <i>Molecular Biology and Evolution</i> , <b>2013</b> , 30, 1263-9	8.3	28
26	The effect of gene overlapping on the rate of RNA virus evolution. <i>Molecular Biology and Evolution</i> , <b>2013</b> , 30, 1916-28	8.3	37
25	Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality. <i>Retrovirology</i> , <b>2013</b> , 10, 114	3.6	13
24	Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation. <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002904	6	6

23	Level of gene expression is a major determinant of protein evolution in the viral order Mononegavirales. <i>Journal of Virology</i> , <b>2012</b> , 86, 5253-63	6.6	14
22	Why do RNA viruses recombine?. <i>Nature Reviews Microbiology</i> , <b>2011</b> , 9, 617-26	22.2	381
21	RNA structures, genomic organization and selection of recombinant HIV. <i>RNA Biology</i> , <b>2011</b> , 8, 280-6	4.8	18
20	RNA structures facilitate recombination-mediated gene swapping in HIV-1. <i>Journal of Virology</i> , <b>2010</b> , 84, 12675-82	6.6	45
19	Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000418	7.6	63
18	Implications of recombination for HIV diversity. <i>Virus Research</i> , <b>2008</b> , 134, 64-73	6.4	58
17	Identifying the important HIV-1 recombination breakpoints. <i>PLoS Computational Biology</i> , <b>2008</b> , 4, e1000178	5.7	55
16	Sequence determinants of breakpoint location during HIV-1 intersubtype recombination. <i>Nucleic Acids Research</i> , <b>2006</b> , 34, 5203-16	20.1	48
15	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> ,	50.4	34
14	Introductions and early spread of SARS-CoV-2 in France		11
13	Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine		4
12	Early phylodynamics analysis of the COVID-19 epidemic in France		6
11	Capturing diverse microbial sequence with comprehensive and scalable probe design		2
10	Genetic diversity of Collaborative Cross mice controls viral replication, clinical severity and brain pathology induced by Zika virus infection, independently of Oas1b		2
9	The B.1.351 and P.1 variants extend SARS-CoV-2 host range to mice		62
8	A new SARS-CoV-2 variant poorly detected by RT-PCR on nasopharyngeal samples, with high lethality		4
7	Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen		2
6	Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals		82

5	A novel SARS-CoV-2 related coronavirus in bats from Cambodia	29
4	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	45
3	A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in mice	1
2	Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH	6
1	A mouse-adapted SARS-CoV-2 strain replicating in standard laboratory mice	6